Also, in a randomized study of atRA in 1100 adults <60 years with AML, atRA, started on treatment day 6, did not reveal any consistent benefit in either the entire cohort or in the subgroup of patients with NPM1 mutations [78]. The gene discussed is NPM1; the disease is acute myeloid leukemia.